L'égalité dans la mire, l'inégalité dans la peau : comprendre l'écart entre les attentes et la réalité des parents dans le partage des tâches

Le présent mémoire s’intéresse à l’écart qui existe entre la volonté admise des individus de partager les tâches domestiques et parentales de manière égalitaire et les données d’enquête qui font état de l’inégalité qui subsiste tant dans le temps alloué que dans le type d’activités exécutées par les hommes et les femmes. En se penchant sur la manière dont s’organisent les pratiques domestiques et parentales, cette étude a pour objectif de cerner sur quoi reposent les sentiments de satisfaction et d’insatisfaction des parents québécois. Les résultats tirés d’une démarche qualitative d’enquête par entretiens menée auprès de huit hommes et huit femmes montrent que les individus conçoivent toujours les deux genres comme fondamentalement différents et leurs rôles comme complémentaires. Ce faisant, bien qu’ils disent adhérer fortement à l’égalité, ils aspirent plutôt à des rapports équitables, ce qui contribue à expliquer pourquoi l’égalité n’est jamais atteinte

Radio Galaxy Zoo: host galaxies and radio morphologies derived from visual inspection

We present results from the first 12 months of operation of Radio Galaxy Zoo, which upon completion will enable visual inspection of over 170 000 radio sources to determine the host galaxy of the radio emission and the radio morphology. Radio Galaxy Zoo uses 1.4 GHz radio images from both the Faint Images of the Radio Sky at Twenty Centimeters (FIRST) and the Australia Telescope Large Area Survey (ATLAS) in combination with mid-infrared images at 3.4 µm from the Wide-field Infrared Survey Explorer (WISE) and at 3.6 µm from the Spitzer Space Telescope. We present the early analysis of the WISE mid-infrared colours of the host galaxies. For images in which there is >75 per cent consensus among the Radio Galaxy Zoo cross-identifications, the project participants are as effective as the science experts at identifying the host galaxies. The majority of the identified host galaxies reside in the midinfrared colour space dominated by elliptical galaxies, quasi-stellar objects and luminous infrared radio galaxies. We also find a distinct population of Radio Galaxy Zoo host galaxies residing in a redder mid-infrared colour space consisting of star-forming galaxies and/or dustenhanced non-star-forming galaxies consistent with a scenario of merger-driven active galactic nuclei (AGN) formation. The completion of the full Radio Galaxy Zoo project will measure the relative populations of these hosts as a function of radio morphology and power while providing an avenue for the identification of rare and extreme radio structures. Currently, we are investigating candidates for radio galaxies with extreme morphologies, such as giant radio galaxies, late-type host galaxies with extended radio emission and hybrid morphology radio sources. Key words: methods: data analysis – infrared: galaxies – radio continuum: ga

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

INTRODUCTION: We evaluated tissue tumor mutational burden (tTMB) and mutations in STK11, KEAP1, and KRAS as biomarkers for outcomes with pembrolizumab plus platinum-based chemotherapy (pembrolizumab-combination) for NSCLC among patients in the phase 3 KEYNOTE-189 (ClinicalTrials.gov, NCT02578680; nonsquamous) and KEYNOTE-407 (ClinicalTrials.gov, NCT02775435; squamous) trials. METHODS: This retrospective exploratory analysis evaluated prevalence of high tTMB and STK11, KEAP1, and KRAS mutations in patients enrolled in KEYNOTE-189 and KEYNOTE-407 and the relationship between these potential biomarkers and clinical outcomes. tTMB and STK11, KEAP1, and KRAS mutation status was assessed using whole-exome sequencing in patients with available tumor and matched normal DNA. The clinical utility of tTMB was assessed using a prespecified cutpoint of 175 mutations/exome. RESULTS: Among patients with evaluable data from whole-exome sequencing for evaluation of tTMB (KEYNOTE-189, n = 293; KEYNOTE-407, n = 312) and matched normal DNA, no association was found between continuous tTMB score and overall survival (OS) or progression-free survival for pembrolizumab-combination (Wald test, one-sided p \u3e 0.05) or placebo-combination (Wald test, two-sided p \u3e 0.05) in patients with squamous or nonsquamous histology. Pembrolizumab-combination improved outcomes for patients with tTMB greater than or equal to 175 compared with tTMB less than 175 mutations/exome in KEYNOTE-189 (OS, hazard ratio = 0.64 [95% confidence interval (CI): 0.38‒1.07] and 0.64 [95% CI: 0.42‒0.97], respectively) and KEYNOTE-407 (OS, hazard ratio = 0.74 [95% CI: 0.50‒1.08 and 0.86 [95% CI: 0.57‒1.28], respectively) versus placebo-combination. Treatment outcomes were similar regardless of KEAP1, STK11, or KRAS mutation status. CONCLUSIONS: These findings support pembrolizumab-combination as first-line treatment in patients with metastatic NSCLC and do not suggest the utility of tTMB, STK11, KEAP1, or KRAS mutation status as a biomarker for this regimen

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – characterized by some benefit but only rare durable responses – was the only treatment option for patients with NSCLC whose tumors lacked targetable mutations. By contrast, immune checkpoint inhibitors have demonstrated distinctly durable responses and represent the advent of a new treatment approach for patients with NSCLC. Three immune checkpoint inhibitors, pembrolizumab, nivolumab and atezolizumab, are now approved for use in first- and/or second-line settings for selected patients with advanced NSCLC, with promising benefit also seen in patients with stage III NSCLC. Additionally, durvalumab following chemoradiation has been approved for use in patients with locally advanced disease. Due to the distinct features of cancer immunotherapy, and rapid progress in the field, clinical guidance is needed on the use of these agents, including appropriate patient selection, sequencing of therapies, response monitoring, adverse event management, and biomarker testing. The Society for Immunotherapy of Cancer (SITC) convened an expert Task Force charged with developing consensus recommendations on these key issues. Following a systematic process as outlined by the National Academy of Medicine, a literature search and panel voting were used to rate the strength of evidence for each recommendation. This consensus statement provides evidence-based recommendations to help clinicians integrate immune checkpoint inhibitors into the treatment plan for patients with NSCLC. This guidance will be updated following relevant advances in the field

CDC's COVID-19 International Vaccine Implementation and Evaluation Program and Lessons from Earlier Vaccine Introductions.

The US Centers for Disease Control and Prevention (CDC) supports international partners in introducing vaccines, including those against SARS-CoV-2 virus. CDC contributes to the development of global technical tools, guidance, and policy for COVID-19 vaccination and has established its COVID-19 International Vaccine Implementation and Evaluation (CIVIE) program. CIVIE supports ministries of health and their partner organizations in developing or strengthening their national capacities for the planning, implementation, and evaluation of COVID-19 vaccination programs. CIVIE's 7 priority areas for country-specific technical assistance are vaccine policy development, program planning, vaccine confidence and demand, data management and use, workforce development, vaccine safety, and evaluation. We discuss CDC's work on global COVID-19 vaccine implementation, including priorities, challenges, opportunities, and applicable lessons learned from prior experiences with Ebola, influenza, and meningococcal serogroup A conjugate vaccine introductions

The PREDICTS database: a global database of how local terrestrial biodiversity responds to human impacts

Biodiversity continues to decline in the face of increasing anthropogenic pressures such as habitat destruction, exploitation, pollution and introduction of alien species. Existing global databases of species’ threat status or population time series are dominated by charismatic species. The collation of datasets with broad taxonomic and biogeographic extents, and that support computation of a range of biodiversity indicators, is necessary to enable better understanding of historical declines and to project – and avert – future declines. We describe and assess a new database of more than 1.6 million samples from 78 countries representing over 28,000 species, collated from existing spatial comparisons of local-scale biodiversity exposed to different intensities and types of anthropogenic pressures, from terrestrial sites around the world. The database contains measurements taken in 208 (of 814) ecoregions, 13 (of 14) biomes, 25 (of 35) biodiversity hotspots and 16 (of 17) megadiverse countries. The database contains more than 1% of the total number of all species described, and more than 1% of the described species within many taxonomic groups – including flowering plants, gymnosperms, birds, mammals, reptiles, amphibians, beetles, lepidopterans and hymenopterans. The dataset, which is still being added to, is therefore already considerably larger and more representative than those used by previous quantitative models of biodiversity trends and responses. The database is being assembled as part of the PREDICTS project (Projecting Responses of Ecological Diversity In Changing Terrestrial Systems – www.predicts.org.uk). We make site-level summary data available alongside this article. The full database will be publicly available in 2015